183 related articles for article (PubMed ID: 21955615)
1. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
4. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
6. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
8. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
9. Antibiotics for the prevention of febrile neutropenia.
Pascoe J; Steven N
Curr Opin Hematol; 2009 Jan; 16(1):48-52. PubMed ID: 19057204
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
11. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
12. [The infectious complications of bronchial cancer].
Klastersky J
Rev Mal Respir; 1998 Sep; 15(4):451-9. PubMed ID: 9805755
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
Lo N; Cullen M
Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
[TBL] [Abstract][Full Text] [Related]
14. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
15. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies.
Urban T; Lebeau B
Eur Respir J; 1999 Jun; 13(6):1228-9. PubMed ID: 10445594
[No Abstract] [Full Text] [Related]
17. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
Saloustros E; Tryfonidis K; Georgoulias V
Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
[TBL] [Abstract][Full Text] [Related]
18. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
Levenga TH; Timmer-Bonte JN
Br J Haematol; 2007 Jul; 138(2):146-52. PubMed ID: 17593021
[TBL] [Abstract][Full Text] [Related]
19. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]